Company profile for SpyGlass Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

SpyGlass Pharma, co-founded by Dr. Malik Y. Kahook, MD, and Glenn Sussman, is dedicated to developing innovative treatments for chronic ophthalmic diseases. The company is built upon technology initially developed at the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine. With a team comprising skilled engineers, scientists, and clinicians, SpyGlass Pharma focuses on creating transformative treatm...
SpyGlass Pharma, co-founded by Dr. Malik Y. Kahook, MD, and Glenn Sussman, is dedicated to developing innovative treatments for chronic ophthalmic diseases. The company is built upon technology initially developed at the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine. With a team comprising skilled engineers, scientists, and clinicians, SpyGlass Pharma focuses on creating transformative treatment options for patients with ophthalmic diseases. Their primary objective is to achieve long-term drug delivery solutions.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
27081 Aliso Creek Rd, Suite 125 Aliso Viejo, CA 92656
Telephone
Telephone
+1 9492846904
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.indianpharmapost.com/biopharma/spyglass-pharma-reports-promising-clinical-trial-results-for-glaucoma-therapy-18243

INDPHARMAPOST
14 Nov 2025

https://www.globenewswire.com/news-release/2025/11/10/3184483/0/en/SpyGlass-Pharma-Announces-Positive-36-Month-First-in-Human-and-3-Month-Phase-I-II-Trial-Results-for-Its-Novel-BIM-IOL-System.html

GLOBENEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/10/14/3166153/0/en/SpyGlass-Pharma-s-Novel-BIM-IOL-System-Demonstrated-a-Statistically-Significant-Reduction-in-Mean-IOP-at-24-Months.html

GLOBENEWSWIRE
14 Oct 2025

https://www.globenewswire.com/news-release/2025/09/16/3150762/0/en/SpyGlass-Pharma-Appoints-Anand-Sundaram-as-Head-of-Commercial.html

GLOBENEWSWIRE
16 Sep 2025

https://www.globenewswire.com/news-release/2025/08/19/3135660/0/en/SpyGlass-Pharma-Appoints-Elizabeth-O-Farrell-to-its-Board-of-Directors.html

GLOBENEWSWIRE
19 Aug 2025

https://www.globenewswire.com/news-release/2025/06/02/3091790/0/en/SpyGlass-Pharma-Raises-75-Million-Series-D-Funding-to-Advance-Its-Long-term-Drug-Delivery-Platform-for-Glaucoma-Patients.html

GLOBENEWSWIRE
02 Jun 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty